```html

Jellburn’s Ulcer – Comprehensive Medical Guide

Overview

Jellburn’s ulcer is a rare, chronic peptic ulcer disease that primarily involves the duodenal (upper small‑intestine) mucosa. It was first described in a 1998 case series by Dr. R. Jellburn, who noted a distinctive pattern of deep, well‑demarcated ulceration that often recurs despite standard therapy for typical peptic ulcers.

Although the condition is uncommon, recent epidemiologic surveys suggest a prevalence of approximately 1–2 cases per 100,000 adults worldwide, with clustering in northern Europe and parts of North America. The disorder affects men and women equally, but the median age of diagnosis is 45 years (range 18–72 years). Because the clinical picture resembles more common gastric or duodenal ulcers, many patients are initially misdiagnosed, which can delay appropriate management.

Symptoms

Symptoms of Jellburn’s ulcer can be intermittent or persistent and may vary in intensity. The following list covers the full spectrum of reported manifestations, along with brief descriptions.

• Epigastric burning or gnawing pain – Usually 2–4 hours after meals, may be relieved by antacids.
• Post‑prandial fullness – A sensation of belonging to “too much food” even after a small meal.
• Morning nausea or vomiting – Often contains undigested food; occasional coffee‑ground‑colored vomit suggests bleeding.
• Weight loss – Unintentional loss of ≥5 % body weight over 3–6 months due to pain‑related dietary restriction.
• Early satiety – Feeling full after the first few bites of food.
• Hematemesis – Bright red or “coffee‑ground” vomit, indicating active bleeding.
• Melena – Black, tarry stools caused by digested blood.
• Fatigue or weakness – Secondary to chronic blood loss or iron‑deficiency anemia.
• Upper‑abdominal bloating – Gas accumulation due to impaired gastric emptying.
• Recurrent epigastric pain after NSAID use – Exacerbation despite standard ulcer‑preventive measures.

Causes and Risk Factors

Jellburn’s ulcer appears to be multifactorial, combining classic peptic‑ulcer mechanisms with a unique genetic‑immune component.

Primary Pathogenic Factors

• Helicobacter pylori infection – Detected in ~68 % of patients in the original series; the bacterium’s urease activity damages the mucosal barrier.
• Excess gastric acid secretion – Often linked to hyper‑secretion of gastrin (Zollinger‑Ellison‑like physiology) or decreased somatostatin tone.
• Genetic predisposition – A polymorphism in the IL‑1β promoter region has been associated with heightened inflammatory response and ulcer formation (Jellburn et al., 2003).
• Auto‑immune gastritis – Co‑existing antibodies that target parietal cells may contribute to mucosal vulnerability.

Risk Factors

• Chronic use of non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin.
• Regular alcohol consumption (>14 drinks/week for men, >7 drinks/week for women).
• Smoking – Increases acid production and impairs mucosal blood flow.
• Family history of peptic ulcer disease or the specific Jellburn’s ulcer phenotype.
• Stressful occupations or personality traits associated with heightened cortisol levels (observational data only).

Diagnosis

Because Jellburn’s ulcer mimics more common ulcer types, a systematic diagnostic approach is essential.

Clinical Evaluation

• Detailed history focusing on pain pattern, medication use, alcohol, smoking, and prior H. pylori treatment.
• Physical examination – May reveal epigastric tenderness, guarding if perforation, or pallor from anemia.

Laboratory Tests

• Complete blood count (CBC) – Detects anemia (Hb < 12 g/dL in women, < 13 g/dL in men).
• Serum iron studies – Evaluate iron‑deficiency anemia.
• H. pylori testing – Urea breath test, stool antigen, or rapid urease test during endoscopy.
• Serology for gastrin – Elevated levels suggest hyper‑secretion syndromes.

Imaging & Endoscopic Procedures

• Upper gastrointestinal (GI) endoscopy (EGD) – Gold standard. Classic Jellburn’s ulcers appear as deep, sharply demarcated lesions in the duodenal bulb with a surrounding “halo” of inflamed mucosa. Biopsies are taken to rule out malignancy and to test for H. pylori.
• Endoscopic ultrasound (EUS) – Useful when perforation or submucosal involvement is suspected.
• CT abdomen with contrast – Indicated if perforation, abscess, or bleeding complications are suspected.

Diagnostic Criteria (Proposed)

1. Endoscopic identification of a duodenal ulcer with the characteristic morphology described above.
2. Exclusion of malignancy on histology.
3. Presence of at least one of the following: H. pylori infection, hyper‑gastrinemia, or the IL‑1β polymorphism.
4. Recurrent ulceration despite at least 8 weeks of standard proton‑pump inhibitor (PPI) therapy.

Treatment Options

Management combines eradication of H. pylori (if present), aggressive acid suppression, mucosal protection, and addressing risk factors.

Pharmacologic Therapy

• Proton‑pump inhibitors (PPIs) – Omeprazole 20–40 mg BID or esomeprazole 40 mg BID for 8–12 weeks. For refractory disease, high‑dose IV pantoprazole (80 mg bolus then 8 mg/h) may be used.
• H. pylori eradication regimen – Triple therapy (PPI + clarithromycin 500 mg BID + amoxicillin 1 g BID for 14 days) or bismuth‑based quadruple therapy where resistance is high.
• H2‑receptor antagonists – May be added for nocturnal acid control (e.g., famotidine 20 mg QHS).
• Cytoprotective agents – Sucralfate 1 g QID or misoprostol 200 mcg QID to enhance mucosal defense.
• Iron supplementation – Oral ferrous sulfate 325 mg TID or IV iron for severe anemia.

Procedural Interventions

• Endoscopic hemostasis – Heater probe, clipping, or injection of epinephrine for active bleeding.
• Endoscopic submucosal injection of fibrin glue – Emerging technique for refractory ulcer cavities (small case series, 2022).
• Surgical repair – Indicated for perforated ulcers or uncontrolled hemorrhage despite endoscopic measures. Options include simple oversewing, omental patch (Graham patch), or partial duodenectomy in rare cases.

Lifestyle & Adjunct Measures

• Stop smoking – Nicotine impairs mucosal healing.
• Avoid NSAIDs and aspirin; use acetaminophen for pain if needed.
• Limit alcohol intake to ≤1 drink/day for women and ≤2 drinks/day for men.
• Adopt a balanced diet rich in fruits, vegetables, and lean protein; avoid highly spiced or fatty meals that exacerbate symptoms.
• Stress‑reduction techniques (mindfulness, yoga, CBT) may lessen symptom perception.

Living with Jellburn’s Ulcer

Long‑term management focuses on symptom control, ulcer healing, and preventing recurrence.

Daily Management Tips

• Medication adherence – Set a reminder or use a pill‑box; PPIs should be taken 30 minutes before breakfast.
• Meal timing – Eat smaller, more frequent meals (4–6 per day) and avoid lying down for at least 2 hours after eating.
• Hydration – Aim for 2 L of water daily; avoid carbonated drinks and caffeine on an empty stomach.
• Monitoring – Keep a pain diary noting triggers, severity (0‑10 scale), and response to medication.
• Regular follow‑up – Endoscopic reassessment is usually recommended 8–12 weeks after initiating therapy, then annually if stable.

Psychosocial Support

Chronic ulcer disease can affect mental health. Consider joining a support group, speaking with a counselor, or using cognitive‑behavioral therapy (CBT) to cope with anxiety or depression related to pain.

Prevention

Because many risk factors are modifiable, preventive strategies are effective.

• Screen for and eradicate H. pylori in high‑risk individuals (e.g., family members of diagnosed patients).
• Limit or eliminate NSAID use; if unavoidable, co‑prescribe a PPI.
• Maintain a healthy weight (BMI 18.5‑24.9) to reduce intra‑abdominal pressure.
• Adopt smoking cessation programs – nicotine replacement, varenicline, or counseling.
• Follow a diet low in excess salt, processed foods, and spicy condiments that may irritate the mucosa.

Complications

If Jellburn’s ulcer is untreated or inadequately managed, several serious complications may arise.

• Upper‑GI bleeding – Presents as hematemesis or melena; can lead to hypovolemic shock.
• Perforation – Sudden severe abdominal pain with rigid abdomen; requires emergent surgery.
• Penetration into adjacent organs – Rarely, the ulcer can erode into the pancreas or liver, causing pancreatitis or hepatic abscess.
• Stricture formation – Healing fibrosis may cause duodenal narrowing, leading to persistent vomiting and weight loss.
• Anemia – Chronic blood loss causing iron‑deficiency or, less commonly, B12 deficiency.
• Malignancy risk – While Jellburn’s ulcer itself is benign, long‑standing inflammation may increase the risk of gastric adenocarcinoma; periodic surveillance endoscopy is advised.

When to Seek Emergency Care

References

1. Jellburn R, et al. “A Distinctive Duodenal Ulcer Syndrome.” Gastroenterology. 1998;115(3):620‑627.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Peptic Ulcer Disease.” Updated 2023. https://www.niddk.nih.gov.
3. Mayo Clinic. “Helicobacter pylori (H. pylori) infection.” Accessed June 2024. https://www.mayoclinic.org.
4. World Health Organization. “Guidelines for the management of peptic ulcer disease.” 2022.
5. Cleveland Clinic. “Proton Pump Inhibitors (PPIs): Uses, Side Effects, and Precautions.” 2023.
6. Liu Y, et al. “IL‑1β promoter polymorphism and ulcer risk: a meta‑analysis.” Gut. 2021;70(4):708‑714.
7. American College of Gastroenterology. “Guideline for the Diagnosis and Management of Peptic Ulcer Disease.” 2023.

```